Tenof EM is a nucleoside reverse transcriptase inhibitor; this is involved in treating HIV infection. Tenof EM tablets eliminate the HIV virus from the blood. Tenof EM is not permanent remedy, it does not cure the disease, but it prevents AIDS. Tenof EM is Available in various dosage forms like tablets, capsules and solution form. Tenof EM is not under the conditions like; Pregnancy, Breastfeeding, Allergic conditions, Lactic acidosis, abnormal liver problems, Kidney problems CD 4+ cells are essential for the prevention of invasion of virus into the body. HIV is eradicate the cells and leads to cause vulnerable condition like AIDS. Tenof EM is useful in the treatment of HIV infection, by improving the CD 4+ cells in the body
Emtricitabine and tenofovir disoproxil fumarate
200mg + 300mg
Tenof EM is primarily indicated for; HIV infection Chronic hepatitis B virus infection
There are two major anti retroviral agents that present in Tenof EM; contains Emtricitabine, tenofovir disoproxil fumarate.
This is one of the active ingredients of Tablet Tenof EM , Emtricitabine is a nucleoside analog of cytidine, various cellular enzymes involved in conversion of Emtricitabine into Emtricitabine 5’-triphosphate. This conversion will prohibit the effect of HIV-1 reverse transcriptase. This binds with deoxycytidine 5’ triphosphate, mingled into viral DNA and chain termination of the cells occur.
Tenofovir disoproxil fumarate
Tenof EM → an acyclic nucleoside phosphonate diester analog of adenosine monophosphate. Tenofovir disoproxil fumarate is converted into tenofovir by diester hydrolysis. Tenofovir is phosphorylated into tenofovir diphosphate by cellular enzymes This inhibits the effect of HIV 1 RT by competing with natural substrate (deoxyadenosine 5’-triphosphate), fusing into DNA, by DNA chain termination.
Tenof EM is rapidly absorbed with peak plasma concentration occurring 1-2 hours.
Tenof EM is highly bound to the human plasma protein over the range of 0.02-200 μg/mL (Emtricitabine) and 0.01–25 μg/mL (tenofovir).
Tenof EM is metabolized and its metabolites are released through urine.
Excretion of tablet Tenof EM occurs through urine. The mean plasma termination half-life period of tablet Tenof EM is Emtricitabine 10 hours (7.4-18.0); tenofovir 17 hours (12.0-25.7). The bioavailability of both Emtricitabine is 92% and tenofovir is 25%
Tenof EM Dosage and administration
Tenof EM ,the dosage prescribed for the treatment of HIV infection; Tenof EM administrated One tablet should be taken as a single dose. Tenof EM is taken orally with or without food
The common effects caused by Tablet Tenof EM
diarrhea, nausea, vomiting
injection site reaction, fatigue
sinusitis, upper respiratory infection, throat infection
Central nervous system
head ache, dizziness, psychiatric disorders, depression, and sleeplessness
Fever, chills Pain during urination Fatigue Chest pain Skin discoloration Numbness, burning or tingling (hands, arm, feet) Itching Muscle stiffness Depression
Severe Acute Exacerbations of Hepatitis B New Onset or Worsening Renal Impairment. Lactic Acidosis/Severe Hepatomegaly with Steatosis Bone Effects of Tenofovir DF. Immune Reconstitution Syndrome.
Some other effects
Anorexia, Dyspepsia, asthenia, dizziness, fatigue, headache, rash, hypophosphatemia, raised liver enzymes, hepatitis, renal effects (e.g. nephritis, nephrogenic diabetes insipidus, proximal renal tubulopathy, renal failure), bone pain, osteomalacia, muscle weakness, myopathy. Rarely, raised serum amylase levels, pancreatitis, and rhabdomyolysis.